Neil Kumar, BridgeBio CEO (J.T. MacMillan Photography for Endpoints News)
October 24, 2024 04:00 PM EDT
R&D
Cell/Gene Tx

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

Lei Lei Wu

News Reporter

Bridge­Bio dis­closed re­sults Thurs­day from a Phase 1/2 study of its gene ther­a­py for Cana­van dis­ease, an ex­treme­ly rare and dev­as­tat­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Roche re­turns to Dyno for its AAV tech with $50M up­front

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times